MASSIDDA: "Nuova disciplina delle attività trasfusionali e della produzione nazionale di emoderivati" (277)

This procedure introduces new regulations for blood transfusion activities and the national production of blood-derived medicines. It aims to ensure safety and efficiency in this critical healthcare sector. The changes will affect blood banks, healthcare providers involved in transfusions, and companies producing blood derivatives. Patients receiving transfusions or treatments with blood products will also be impacted by updated safety standards.